Avraham Pharmaceuticals Company

Avraham Pharmaceuticals (“Avraham”) is a privately held, emerging pharmaceutical company developing novel products for treatment and/or prevention of neurodegenerative disorders. Founded in 2010, Avraham has raised $9 million to conduct a European Phase II proof-of-concept efficacy trial in patients with Alzheimer's disease, supporting the development of its lead product candidate, ladostigil.
Technology: Biotechnology, Health Care, Pharmaceutical
Industry: Preventive Medicine
Headquarters: Yavneh, Israel
Founded Date: 2010
Employees Number: 1-10
Funding Status: N/A

Visit Website
Register and Claim Ownership